TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16485185

Group type: EXPERIMENTAL
Intervention: 2500 units of Factor XIII
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1250 units of Factor XIII
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Factor XIII levels < 70 %
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Factor XIII levels >= 70 %
Number of subjects: 75
Study: 12587945

Group type: EXPERIMENTAL
Intervention: ximelagatran/melagatran (Exanta)
Number of subjects: 0

Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 0
Study: 11304763

Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m²/d for 5 days, every 3 weeks)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 402

Group type: COMPARATOR
Intervention: PE (cisplatin and etoposide)
Number of subjects: 402
Study: 9240874

Group type: EXPERIMENTAL
Intervention: Grade 2 malnourished children
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Grade 3 malnourished children
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study: 8422283

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 4 weeks
Number of subjects: 33
Study: 2442928

Group type: EXPERIMENTAL
Intervention: Epidural analgesia + indomethacin (E + I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (E)
Number of subjects: 24
Study: 31480423

Group type: EXPERIMENTAL
Intervention: Raw garlic consumption (twice or more per week)
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Low raw garlic intake
Number of subjects: 2011
Study: 29231541

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) at Hegu (LI 4) and Neiguan (PC 6) from 30 min before anesthesia induction to the end of operation.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anesthesia group (no electrical stimulation).
Number of subjects: 100
Study: 23566071

Group type: EXPERIMENTAL
Intervention: 5% sterile topical royal jelly
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22100606

Group type: EXPERIMENTAL
Intervention: Ω‐3 PUFAs (2gr/day for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20947171

Group type: EXPERIMENTAL
Intervention: Manual refraction (MR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Autorefraction (AR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pinhole occluder (PH)
Number of subjects: 110
Study: 17618241

Group type: EXPERIMENTAL
Intervention: AcrysofIQ IOL
Number of subjects: 27

Group type: COMPARATOR
Intervention: AcrysofSingle-Piece IOL
Number of subjects: 27
Study: 17176827

Group type: EXPERIMENTAL
Intervention: Salivary nitric oxide levels measured through its product nitrite in patients with lichen planus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salivary nitric oxide levels measured through its product nitrite in patients with recurrent aphthous ulcers
Number of subjects: 0
Study: 14595527

Group type: EXPERIMENTAL
Intervention: Withdrawal of SSRI drugs (intervention group, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No change in treatment (control group, n=35)
Number of subjects: 70
Study: 11110743

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting early switch from intravenous to oral acetaminophen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (all other surgical departments)
Number of subjects: 30
Study: 8811469

Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional flap procedures
Number of subjects: 15
Study: 1326846

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 2500 anti‐XaU once daily
Number of subjects: 141

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 anti‐XaU twice daily
Number of subjects: 141
Study: 3890130

Group type: EXPERIMENTAL
Intervention: L-carnitine, 2 g i.v. three times a week
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 28
Study: 30301358

Group type: EXPERIMENTAL
Intervention: Hand exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (maintained daily routine)
Number of subjects: 60
Study: 29119719

Group type: EXPERIMENTAL
Intervention: Smart Moms intervention (one group session, lessons on a mobile website, and text messages)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Smart Moms intervention
Number of subjects: 51
Study: 27021779

Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS)
Number of subjects: 49
Study: 24607003

Group type: EXPERIMENTAL
Intervention: Investigational vaccine formulations containing dPly alone (10 or 30 μg) or both dPly and PhtD (10 or 30 μg each)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Polysaccharide conjugate-containing formulations
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group receiving 23-valent pneumococcal polysaccharide vaccine (23PPV) followed by placebo
Number of subjects: 156
Study: 23063288

Group type: EXPERIMENTAL
Intervention: Dementia patients prescribed warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater nursing staff time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nursing home residents without dementia
Number of subjects: 0
Study: 20619385

Group type: EXPERIMENTAL
Intervention: Compatible tool transformations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incompatible tool transformations
Number of subjects: 0
Study: 18597602

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated pockets)
Number of subjects: 16
Study: 15795711

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 mEq over 20 minutes, followed by 20 mEq over 2 hours)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 11850760

Group type: COMPARATOR
Intervention: Single drugs (amphetamine, benzphetamine, fenfluramine, sibutramine)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Combination drugs
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Overall medications studied
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Amphetamine, benzphetamine, fenfluramine, sibutramine
Number of subjects: 108
Study: 10329340

Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (tailored skill building and facilitating activities to improve nutrition and increase physical activity)
Number of subjects: 4842

Group type: EXPERIMENTAL
Intervention: Enhanced intervention group
Number of subjects: 4842

Group type: COMPARATOR
Intervention: Minimum intervention group
Number of subjects: 4842
Study: 7867055

Group type: EXPERIMENTAL
Intervention: Blackcurrant drink with 0.103% citrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plain blackcurrant drink
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% sucrose (positive control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% sorbitol (negative control)
Number of subjects: 20
Study: 8444752

Group type: EXPERIMENTAL
Intervention: Clinician-based intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lecture-based intervention
Number of subjects: 20
Study: 3530226

Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Novo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Highly purified porcine insulin (Monocomponent)
Number of subjects: 20
Study: 29462969

Group type: EXPERIMENTAL
Intervention: 500 mL of milk (MILK)
Number of subjects: 18
Study: 26519688

Group type: EXPERIMENTAL
Intervention: Shuanghua Baihe tablets
Number of subjects: 0
Study: 25522565

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 120
Study: 22426673

Group type: EXPERIMENTAL
Intervention: Real exposure to electromagnetic fields from mobile phones for 10 minutes
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham exposure to electromagnetic fields for 10 minutes
Number of subjects: 160
Study: 20826258

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 2416

Group type: COMPARATOR
Intervention: No left ventricular (LV) systolic dysfunction
Number of subjects: 2416
Study: 18446439

Group type: EXPERIMENTAL
Intervention: Higher quality relationships with adult providers (characterized by trust, mutuality, and empathy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower quality relationships with adult providers
Number of subjects: 0
Study: 16001111

Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study: 12655514

Group type: EXPERIMENTAL
Intervention: One course of perioperative chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Low p27 expression
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: High p27 expression
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: HER-2/neu overexpression
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Higher tumor grade
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Low expression of thymidylate synthase
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Higher Ki-67 expression
Number of subjects: 461
Study: 9850028

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CCT)
Number of subjects: 6633

Group type: COMPARATOR
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 6633
Study: 7744132

Group type: EXPERIMENTAL
Intervention: Nimesulide 50 mg bd
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg bd
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg bd
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 2661700

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice per day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 1097490

Group type: EXPERIMENTAL
Intervention: Gerovital H3 (5 ml injection, 3 times a week for first 6 weeks, then 10 ml injection for next 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline, 5 ml injection, 3 times a week for first 6 weeks, then 10 ml injection for next 6 weeks)
Number of subjects: 19
Study: 30728218

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study: 28916443

Group type: EXPERIMENTAL
Intervention: AQ-13 (638.50 mg on days 1 and 2, 319.25 mg on day 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Artemether plus lumefantrine (80 mg artemether and 480 mg lumefantrine twice daily for 3 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AQ-13 (per-protocol analysis)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AQ-13 (intention-to-treat analysis)
Number of subjects: 66
Study: 25091056

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 14 days before surgery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Everyday diet (Control)
Number of subjects: 102
Study: 22494864

Group type: EXPERIMENTAL
Intervention: Moderate dietary weight loss
Number of subjects: 38
Study: 21559037

Group type: EXPERIMENTAL
Intervention: Hand-held bioelectrical impedance analysis (HHBIA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Conventional bioelectrical impedance analysis (CBIA)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Population-specific equation for FFM prediction using CBIA-derived resistance
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Deurenberg equation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Segal equation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All BIA methods
Number of subjects: 98
Study: 17935647

Group type: EXPERIMENTAL
Intervention: Cast iron pots
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Blue steel pots
Number of subjects: 339

Group type: COMPARATOR
Intervention: Oral iron supplements (control)
Number of subjects: 339
Study: 18942523

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional treatment (UFH)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LMWH followed by warfarin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LMWH as a bridge therapy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 155

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 155
Study: 14555312

Group type: EXPERIMENTAL
Intervention: Certoparin (fixed, body-weight-independent dose of 8,000 IU b.i.d. for 8.6 days)
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Unfractionated heparin (IV, adjusted to an 1.5 to 3.0-fold prolongation of the aPTT for 12.0 days)
Number of subjects: 1758
Study: 10703934

Group type: EXPERIMENTAL
Intervention: HRT group (n = 145) received a sequential combination of 2 mg estradiol valerate and 1 mg CPA with or without vitamin D3, 100‐300 IU + 500 mg calcium lactate/day (equal to 93 mg Ca2+)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Non-HRT group (n = 177) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day
Number of subjects: 322

Group type: COMPARATOR
Intervention: Non-HRT group (n = 177) with ER genotypes PP and Pp
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: HRT group (n = 145)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Non-HRT group (n = 177)
Number of subjects: 322
Study: 9083708

Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8356542

Group type: EXPERIMENTAL
Intervention: Rectal hydrophilic gel of methohexital (25 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous administration of methohexital
Number of subjects: 11
Study: 3324991

Group type: EXPERIMENTAL
Intervention: Athermic laser therapy (HeNe 632.8 nm and IR diode 904 nm) for 15 minutes over 10 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (switched-off laser) for 15 minutes over 10 days
Number of subjects: 64
Study: 30031217

Group type: EXPERIMENTAL
Intervention: Extended-release morphine 20 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27562713

Group type: EXPERIMENTAL
Intervention: Tailored DXA result letter and educational brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 7749
Study: 25308301

Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 66

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 66
Study: 22928495

Group type: EXPERIMENTAL
Intervention: Guaiazulene (GA) containing local pomade (0.05 g/100 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Extended antifungal treatment (Control)
Number of subjects: 30
Study: 20200165

Group type: EXPERIMENTAL
Intervention: Treatment for silent GERD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18843868

Group type: EXPERIMENTAL
Intervention: Navigation TKA
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 180
Study: 16373898

Group type: EXPERIMENTAL
Intervention: 20 mg/day ranirestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg/day ranirestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14746386

Group type: EXPERIMENTAL
Intervention: Sleep phase advanced by 3 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sleep phase advanced by 6 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Administration of 400 mg of caffeine 30 minutes prior to lights out
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline night (normal sleep)
Number of subjects: 50
Study: 10926393

Group type: EXPERIMENTAL
Intervention: Alcoholic-hand-gel regimen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Soap-and-water hand washing
Number of subjects: 32
Study: 9017044

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide, 2 drops
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1997044

Group type: COMPARATOR
Intervention: M6G 30 micrograms kg‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: M6G 60 micrograms kg‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Morphine sulphate 120 micrograms kg‐1
Number of subjects: 6
Study: 7076516

Group type: EXPERIMENTAL
Intervention: Two meals per day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Six meals per day
Number of subjects: 8
Study: 30835844

Group type: EXPERIMENTAL
Intervention: General practice recruitment strategies
Number of subjects: 5833

Group type: EXPERIMENTAL
Intervention: Geographic and demographic factors
Number of subjects: 5833

Group type: EXPERIMENTAL
Intervention: Time from GP enrolment to first randomisation
Number of subjects: 5833
Study: 29848335

Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation (UNIMMAP composition), provided bi-monthly and twice-weekly respectively.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation.
Number of subjects: 0
Study: 26414645

Group type: EXPERIMENTAL
Intervention: Postoperative endorectal balloon (RB) inflation (GII)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No endorectal balloon (GI)
Number of subjects: 50
Study: 24496740

Group type: EXPERIMENTAL
Intervention: Aerosolized spray of neosynephrine/4% plain lidocaine mixture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Syringe application of neosynephrine/4% plain lidocaine mixture
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cost analysis of disposable spray tips
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cost analysis of syringes
Number of subjects: 108
Study: 22106323

Group type: EXPERIMENTAL
Intervention: 14‐day very low‐calorie diet (VLCD) regimen
Number of subjects: 298

Group type: COMPARATOR
Intervention: No preoperative dietary restriction (control group)
Number of subjects: 298
Study: 19619690

Group type: EXPERIMENTAL
Intervention: 4 g/d prescription omega-3-acid ethyl esters (P-OM3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16413134

Group type: EXPERIMENTAL
Intervention: PTSD subjects (childhood trauma)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PTSD subjects (adult trauma)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PTSD subjects (both childhood and adult trauma)
Number of subjects: 89
Study: 14643578

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / Hydrochlorothiazide 12.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg / Hydrochlorothiazide 25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 120
Study: 10932895

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both SLT and ALT
Number of subjects: 27
Study: 9199728

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration 0.05%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration 0.1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blood alcohol concentration 0.0% (placebo)
Number of subjects: 18
Study: 1608850

Group type: EXPERIMENTAL
Intervention: 30 mg phenytoin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 100 mg phenytoin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3899397

Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg single oral dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine plus sulfadoxine-pyrimethamine
Number of subjects: 100
Study: 31784339

Group type: EXPERIMENTAL
Intervention: Implementation intentions (II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Typical instruction group
Number of subjects: 42
Study: 31067369

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 28668573

Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (30μg HA with aluminum hydroxide adjuvant)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (15μg HA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (30μg HA without adjuvant)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 25055880

Group type: EXPERIMENTAL
Intervention: BFR-C (continuous at 80% resting systolic blood pressure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BFR-I (intermittent at 130% resting systolic blood pressure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HL (heavy load at 80% one-repetition maximum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LL (light load at 20% one-repetition maximum)
Number of subjects: 12
Study: 22889512

Group type: EXPERIMENTAL
Intervention: ADF-HF (45% fat)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ADF-LF (25% fat)
Number of subjects: 32
Study: 21388839

Group type: COMPARATOR
Intervention: Conventional Catheters (CC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manually Steerable Catheters (MSC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Robotic Catheters (RC)
Number of subjects: 10
Study: 19185404

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based regimen
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study: 16677265

Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 mg.kg(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 45